The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2026:
Anders Bladh (Ribbskottet AB),
Derek Maetzold (Castle Biosciences Inc)
Maria Anderkvist (Coeli Wealth Management),
Jesper Høiland (Chairman of the Board).
The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on June 17, 2025.
The Annual General Meeting of SciBase Holding AB (publ) will be held on May 19, 2026 in Stockholm.
Shareholders who wish to have an item considered by the nominating committee can do this in writing to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm or by e-mail to [email protected] Att: Chairman of the Board (who is the convenor of the nominating committee).
Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.
Stockholm, October 22, 2025
SciBase Holding AB (publ)
For more information, please contact: Jesper Høiland, Chairman of the board, phone +45 612 207 30
Michael Colérus, CFO, phone +46 70 341 34 72
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
SWEDEN - September 26, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, announced today the publication of a collaborative scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used in an atopic dermatitis model to assess factors in human excised skin samples, demonstrating Nevisense to measure skin barrier integrity and monitor changes to the skin barrier function during inflammatory states, such as during eczema and atopic dermatitis.
In the study, human ex vivo skin samples were exposed to inflammatory cytokines IL-4, IL-13 and IL-22, resembling a similar inflammatory response in skin lesions from patients with atopic dermatitis. Nevisense EIS measurements showed to be highly sensitive to detect this inflammatory disruption of the skin barrier function over time. Pivotal genes that play a role in skin barrier changes and type-2 response have been identified. More importantly, genes involved in the restoration of skin inflammation and barrier function by medication with dupilumab were identified in the study. The study therefore emphasizes the potential of Nevisense to be used in measuring and monitoring skin barrier integrity during different disease states of atopic dermatitis, including treatment monitoring.
Skin barrier research is a fast-growing field in dermatology, including the development of new diagnostic methods, therapeutics, aesthetic products, and scientific investigations of diseases related to the skin barrier. Disruption of skin barrier function plays a key role in the development and severity of several skin diseases such as atopic dermatitis.
"We are very encouraged to see that EIS measurements could determine skin barrier integrity and monitor changes to the skin barrier function during type 2 and non type 2 skin inflammation in an atopic dermatitis model. EIS provides an increasingly useful tool for the better understanding of molecular mechanisms of skin barrier integrity" said Professor Cezmi Akdis at SIAF (Swiss Institute of Asthma and Allergy Research).
"We are happy to see that Nevisense and the EIS-technology continue to provide value in this type of research. This study further strengthens the role of Nevisense as an effective research device and show the potential to become the state-of-the-art research tool within the skin barrier research," said Pia Renaudin, CEO of SciBase.
The full results of the study have now been published in the scientific journal Allergy "Distinct Roles of IL-4, IL-13, and IL-22 in Human Skin Barrier Dysfunction and Atopic Dermatitis" - D'Avino - Allergy, DOI: http://doi.org/10.1111/all.70060.
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
SWEDEN - September 23, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received the initial order for a clinical study under the collaboration with Castle Biosciences. The order consists of Nevisense Go and electrodes to a value of around $0.8 million or approximately MSEK 8.
As previously announced on June 16th, 2025, SciBase has entered into a collaboration and license agreement with Castle Biosciences (Nasdaq: CSTL), a US-based leader in molecular diagnostics. The initial collaboration project is to develop a test that predicts flares in patients diagnosed with atopic dermatitis (AD). This order is for products to be used in a clinical study for the first project. Deliveries are expected to start in Q4 2025.
As outlined in the collaboration agreement, Castle invested in SciBase and is now SciBase’s second largest shareholder.
"The collaboration with Castle Biosciences is moving forward at a fast pace and this first order signals the initiation of our first joint study," said Pia Renaudin, CEO of SciBase. "At SciBase we are very excited to, together with Castle Biosciences, help patients with skin barrier dysfunctions get access to more effective therapies."
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CEST on September 23, 2025.
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
SWEDEN - September 10, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, today announces that Ribbskottet AB, the company's largest owner, and Life Science Investment Fund, each has purchased approximately 7.5 million shares in SciBase in a block trade which occurred on Tuesday off the stock exchange from larger long-term owners.
"SciBase continues to impress through rapid growth and interesting collaborations, most recently with Castle Biosciences Inc, while the market still does not seem to have grasped what SciBase is achieving in skin and cancer analysis. When this stake emerged at an attractive price, Ribbskottet therefore did not hesitate to increase its position in the company," said Anders Bladh CEO of Ribbskottet AB.
Jan Poulsen, CEO at Life Science Invest Fund (LSIF), says: "With this additional investment we are happy to strengthen our ownership in SciBase as we believe SciBase is on track for an exciting journey in the coming years and is a very compelling investment case at this low valuation".
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570 E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
SWEDEN - August 28, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, today announces the recent publication of the article "The Importance of Reader Studies in Dermatology" by Dr. Alexander Meves from the Mayo Clinic, in the peer-reviewed journal Dermatology by Karger (DOI: 10.1159/000548165). The article underscores the value of reader studies in validating new dermatology technologies, with Nevisense, SciBase's electrical impedance spectroscopy (EIS) system, featured as a key example.
Reader studies are a well-established methodology across medicine-in radiology, cardiology, and pathology-used to evaluate diagnostic accuracy and ensure new technologies perform reliably in real-world practice. The publication confirms that Nevisense improves biopsy decision-making for suspicious pigmented lesions and enhances diagnostic accuracy.
"Reader studies have long been a gold standard across medicine to validate diagnostic technologies in real-world settings," said Dr. Alexander Meves, Department of Dermatology, Mayo Clinic. "Our findings show that Nevisense brings measurable improvements in diagnostic accuracy, providing dermatologists with a reliable adjunct to dermoscopy in the evaluation of melanoma. With the rapid development of augmented intelligence (AuI)-based technologies and novel diagnostic tools, reader studies offer a rigorous pathway to validate performance, reduce variability in clinical decision-making, and ensure patient benefit."
Pia Renaudin, CEO of SciBase, added: "This independent publication strengthens the evidence base for Nevisense and demonstrates that it has been validated in the same rigorous way that transformative technologies in radiology and cardiology have been. We are proud to see Nevisense recognized in this way and to support dermatologists with technology that help them make better decisions and improve patient outcomes."
The article is published by Karger, one of the world's leading independent medical and scientific publishers with over 130 years of history in advancing health sciences through high-quality, peer-reviewed research. Its journal Dermatology is a globally respected platform for the latest clinical and translational advances in skin health.
The article *"The Importance of Reader Studies in Dermatology"* is available online at *Dermatology*: https://karger.com/drm/article/doi/10.1159/000548165/933589/The-Importance-of-Reader-Studies-in-Dermatology
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
Net sales were TSEK 8,791 (6,641), +32%, cleared for currency effects +40%.
The loss after tax was TSEK 26,589 (15,050).
The loss per share was SEK 0.08 (0.08).
The cash flow from current operations was negative in the amount of TSEK 20,466 (15,179).
The gross margin was 66.2% (69.1%).
Electrode sales volume increased by 30% and was 18,390 (14,016) units. Repeat sales of electrodes to existing customers increased by 39%.
The first half-year in figures
Net sales were TSEK 17,648 (12,699), +39%, cleared for currency effects +43%.
The loss after tax was TSEK 54,100 (25,911).
The loss per share was SEK 0.17 (0.19).
The cash flow from current operations was negative in the amount of TSEK 46,467 (28,360).
The gross margin was 68.4% (69.5%).
Electrode sales volume increased by 30% and was 36,268 (27,868) units. Repeat sales of electrodes to existing customers increased by 29%.
Important events during the quarter
Overall sales increased by 32% (+40%, before currency effects). Sales in Germany within the skin cancer segment increased by 5%(11% in local currency). Sales in the US skin cancer market increased by 308% (345% in local currency) while the sales within the skin barrier segment decreased by 64%.
SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and carries out a directed share issue of approximately MSEK 30 of which Castle Biosciences signs approximately MSEK 19. The remaining MSEK 11 was subscribed by Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS and Ribbskottet AB.
In the period the first order from an Italian dermatology practice was received, marking a major step forward in the company’s European expansion strategy. This follows the registration of Nevisense in Italy in February and the launch of the regional Italian version in April.
SciBase announced the launch of the next generation of Nevisense; Nevisense V. The new platform includes both hardware updates and new features specifically designed for both skin cancer diagnostics and research applications.
In the period SciBase launched a Nevisense Self-Pay Program in the US, a new initiative designed to improve patient access to the Nevisense test outside of traditional insurance coverage.
In the period a major milestone was passed with more than 300,000 Nevisense melanoma detection tests used on patients globally.
The AGM was held on June 17th, and the annual report of 2024 was published on May 23rd.
Important events after the end of the period
A new important customer in the US, Palm Beach Dermatology Group, has placed an initial order for 6 Nevisense.
A new Nevisense pilot was launched at leading University in Southeast Florida.
The directed issue to Castle Biosciences was finalized and raised MSEK 19.
July 1, 2024 -
Apr 1 - June 30
Apr 1 - June 30
June 30, 2025
Jan 1 - Dec 31
THE GROUP
2025
2024
2025
2024
Rolling-12
2023
Net sales, SEK ths
8 791
6 641
17 648
12 699
34 653
29 705
Gross margin, %
66,2%
69,1%
68,4%
69,5%
70,2%
71,0%
Equity/Asset ratio, %
61,1%
71,8%
61,1%
71,8%
67,3%
59,4%
Net indebtness, multiple
0,64
0,39
0,64
0,39
0,49
0,68
Cash equivalents, SEK ths
23 958
43 271
23 958
43 271
23 958
11 245
Cashflow from operating activities, SEK ths
-20 466
-15 179
-46 467
-28 360
-75 490
-57 383
Earnings per share (before and after dilution), SEK
-0,08
-0,08
-0,17
-0,19
-0,33
-0,34
Shareholder's equity per share, SEK
0,10
0,28
0,10
0,39
0,16
0,21
Average number of shares, 000'*
338 296
186 303
318 503
136 449
269 021
177 994
Number of shares at closing of period, 000'*
366 296
219 538
366 296
219 538
366 296
219 538
Share price at end of period, SEK
0,38
0,51
0,38
0,51
0,38
0,41
Number of sold electrodes, pieces
18 398
14 016
36 268
27 868
70 610
62 210
Average number of employees
35
27
34
27
32
28
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August19, 2025.
This interim report has not been subject to review by the Company’s auditors
This report, together with previously published interim reports, can be found in its entirety on the company's website: http://investors.scibase.se/en/reports-and-presentations
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
On 16 June 2025, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's Board of Directors resolved, pursuant to the authorisation granted by the annual general meeting held on 13 June 2024, on a directed share issue, with deviation from the existing shareholders' preferential rights, of approximately SEK 19 million to Castle Biosciences, Inc. ("Castle Biosciences") (the "Directed Issue"). The subscription price in the Directed Issue amounted to SEK 0.40 per share. Castle Biosciences' undertaking to subscribe for shares in the Directed Issue was conditional upon a notification that the application is left without action or approval of the investment from the Swedish Inspectorate of Strategic Products (the "ISP"), pursuant to the Swedish Screening of Foreign Direct Investment Act (2023:560). ISP has notified that the application is left without action and all shares in the Directed Issue have now been subscribed for. The Board of Directors of SciBase has therefore today, on 1 August 2025, resolved on allocation of all shares in the Directed Issue.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN SCIBASE HOLDING AB (PUBL). SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT.
Allotment of shares Castle Biosciences' undertaking to subscribe for shares in the Directed Issue was conditional upon a notification that the application is left without action or approval of the investment from the ISP, pursuant to the Swedish Screening of Foreign Direct Investment Act (2023:560). ISP has notified that the application is left without action and all shares in the Directed Issue have now been subscribed for. The Board of Directors of SciBase has therefore today, on 1 August 2025, resolved to allot all shares in the Directed Issue to Castle Biosciences.
Number of shares and share capital
Through the Directed Issue, the Company's share capital will increase by SEK 2,394,347.50 through the issuance of 47,886,950 new shares. The Directed Issue entails a dilution for existing shareholders of approximately 11.6 percent of the total number of shares in the Company.
Advisors
Vator Securities is the financial advisor and Advokatfirman Schjødt is the legal advisor to SciBase in connection with the Directed Issue.
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, email: [email protected]
The information was submitted for publication, through the agency of the contact persons set out above, at 09.00 CEST on 1 August 2025.
SciBase is a global medical technology company specialising in early detection and prevention in dermatology. SciBase develops and sells Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to improve diagnostic accuracy and thereby ensure the prevention of skin diseases.
Our commitment is to minimise patient suffering, enable doctors to improve and save lives through early detection and reduce healthcare costs.
Based on more than 20 years of research at Karolinska Institutet in Stockholm, SciBase is a leader in dermatological development.
The company is listed on Nasdaq First North Growth Market since 2 June 2015. For more information visit www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/sv/pressmeddelanden.
Important information
The release, publication or distribution of this press release may, in certain jurisdictions, be restricted by law and persons in the jurisdictions where this press release has been published or distributed should inform themselves about and observe any such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any SciBase securities in any jurisdiction, neither from SciBase nor from anyone else.
This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared by the Company in connection with the Directed Issue.
This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, Switzerland, the United States or any other jurisdiction where such announcement, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.
The Company considers that it is engaged in activities worthy of protection under the FDI Act. In accordance with the FDI Act, the Company must inform prospective investors that the Company's activities may fall within the scope of the regulation and that the investment may be notifiable. In the event that an investment is notifiable, it must be notified to the Swedish Inspectorate for Strategic Products ("ISP") prior to its realization. An investment may be notifiable if (i) the investor, any member of its ownership structure or any person on whose behalf the investor is acting, after the investment is made, holds voting rights equal to or exceeding any of the thresholds of 10, 20, 30, 50, 65 or 90 per cent of the total voting rights in the Company, (ii) the investor acquires the Company through the investment and the investor any member of its ownership structure or any person on whose behalf the investor is acting, directly or indirectly, would hold 10 per cent or more of the total voting rights in the Company; and iii) the investor, any member of its ownership structure or any person on whose behalf the investor is acting, would acquire through the investment a direct or indirect influence in the management of the Company. An administrative fine may be imposed on the investor if a notifiable investment is made before the ISP has either (i) decided to leave the notification without action or (ii) approved the investment. Each shareholder should consult an independent legal advisor regarding the possible application of the FDI Act in relation to the Rights Issue for the individual shareholder.
Forward-looking statements This press release contains forward-looking statements that reflect the Company's intentions, beliefs or expectations regarding the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by the use of words such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "anticipates", "should", "could" and, in each case, the negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialise or that they are accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements contained in this press release are accurate and any reader of this press release should not place undue reliance on the forward-looking statements contained in this press release. The information, opinions and forward-looking statements expressed or implied herein are made only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, except as required by law or Nasdaq First North Growth Market's Rule Book for Issuers.
SWEDEN - July 9, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that a private research university in south Florida will pilot the integration of Nevisense into their skin cancer detection workflow.
The pilot will further establish the optimal use of Nevisense for the early detection of skin cancer at point-of-care in all dermatological settings.
The University is globally recognized as leaders in the diagnosis and treatment of dermatological conditions and disorders of the skin. Their faculty includes a number of notable academics, including Nobel Prize recipients and globally recognized experts across nearly every academic discipline, and is classified among "Doctoral Universities: Very High Research Activity". In addition to research, the University maintains several university-wide research centers, including a data center that conducts data-driven research to identify solutions to various world problems and challenges, and a specialized European Center that serves as a consortium to promote and research economic, social, and political issues of interest to the European Union.
"We are honored to collaborate with such a prestigious and well-established educational and innovative University. The pilot will provide the University's patients access to the Nevisense test, and help clinicians attain optimal outcomes in early detection of skin cancer", said Pia Renaudin, CEO of SciBase.
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
SWEDEN - July 7, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, is pleased to announce that Palm Beach Dermatology Group has purchased Nevisense, diagnostic platform, to enhance early detection of melanoma. The initial order, which has been delivered, consists of 6 Nevisense and electrodes to an approximative total order value of KUSD 50 and will generate recurring electrodes sales.
For more than 30 years, Palm Beach Dermatology Group has been a leader in skin care. They focus on advanced treatments, putting patients first, and clinical research. By adding Nevisense, they now offer a non-invasive, AI-based diagnostic tool at point of care.
Melanoma, the deadliest form of skin cancer, remains a serious and growing public health concern in the United States. According to the American Cancer Society, an estimated 190,000 new cases of melanoma will be diagnosed in the U.S. in 2025. Tragically, approximately 8,290 people are expected to die from melanoma this year. However, early detection is key - when found at an early stage, melanoma has an almost 100% cure rate.
"At Palm Beach Dermatology Group, we are always looking to integrate the most innovative and evidence-based technologies into our practice," said Dr. Adam Plotkin, dermatologist and CEO of Palm Beach Dermatology Group. "Nevisense offers a layer of key diagnostic data that will help us detect melanoma at earlier stages, which can make a life-saving difference."
We're excited to have Palm Beach Dermatology Group join our growing network of clinical partners. Known for their excellent patient care and strong research program, it makes them an ideal champion for Nevisense in Florida. Together, we're setting a new standard for melanoma detection," said Pia Renaudin, CEO of SciBase.
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
